Protara Therapeutics (TARA) Operating Income (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Operating Income of -$19.6 million for Q1 2026, down 38.98% year-over-year from -$32.2 million in Q1 2025, and down 2.88% quarter-over-quarter from -$19.1 million in Q4 2025.
Protara Therapeutics (TARA) Operating Income (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Operating Income for 14 consecutive years, with -$19.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 38.98% year-over-year to -$19.6 million; the TTM figure through Mar 2026 stood at -$70.1 million (down 36.22% YoY), while the FY2025 annual figure was -$64.5 million, down 31.32% from the prior year.
- Operating Income declined to -$19.6 million in Q1 2026 per TARA's latest filing, from -$19.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$8.0 million in Q3 2022 and bottomed at -$39.5 million in Q4 2022.
- Historically, Operating Income has averaged -$14.4 million across 5 years, with a median of -$12.1 million in 2023.
- Annual changes were most pronounced in 2022 — Operating Income slumped 284.07% — and 2023, when it jumped 72.05%.
- Protara Therapeutics' Operating Income stood at -$39.5 million in 2022, then surged by 72.05% to -$11.0 million in 2023, then declined by 29.63% to -$14.3 million in 2024, then tumbled by 33.31% to -$19.1 million in 2025, then retreated by 2.88% to -$19.6 million in 2026.
- Business Quant data shows TARA's Operating Income at -$19.6 million in Q1 2026, -$19.1 million in Q4 2025, and -$14.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | -23.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.32 Mn |
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -19.08 Mn |
| Sep 30, 2025 | -14.76 Mn |
| Jun 30, 2025 | -16.59 Mn |
| Mar 31, 2025 | -14.12 Mn |
| Dec 31, 2024 | -14.31 Mn |
| Sep 30, 2024 | -12.33 Mn |
| Jun 30, 2024 | -10.66 Mn |
| Mar 31, 2024 | -11.85 Mn |
| Dec 31, 2023 | -11.04 Mn |
| Sep 30, 2023 | -10.70 Mn |
| Jun 30, 2023 | -12.14 Mn |
| Mar 31, 2023 | -9.73 Mn |
| Dec 31, 2022 | -39.51 Mn |
| Sep 30, 2022 | -7.97 Mn |
| Jun 30, 2022 | -8.71 Mn |
| Mar 31, 2022 | -10.87 Mn |
| Dec 31, 2021 | -10.29 Mn |
| Sep 30, 2021 | -10.83 Mn |